
Sign up to save your podcasts
Or


The JournalFeed podcast for the week of June 22-26, 2026.
These are summaries from just 2 of the 5 articles we cover every week! For access to more, please visit JournalFeed.org for details about becoming a member.
Thursday’s Spoon Feed:
Tirofiban resulted in greater 90-day excellent neurological outcomes vs. placebo in patients with no medium or large vessel occlusion (LVO) who were not improving with with tenecteplase (TNK), NNT = 9.
Friday’s Spoon Feed:
Dual antiplatelet therapy (DAPT) with ticagrelor plus aspirin vs. placebo in patients with stroke treated with thrombolysis resulted in better 90-day excellent neurological outcome, NNT = 15, without a significant increase in symptomatic intracranial hemorrhage (sICH).
By Nick Zelt5
1919 ratings
The JournalFeed podcast for the week of June 22-26, 2026.
These are summaries from just 2 of the 5 articles we cover every week! For access to more, please visit JournalFeed.org for details about becoming a member.
Thursday’s Spoon Feed:
Tirofiban resulted in greater 90-day excellent neurological outcomes vs. placebo in patients with no medium or large vessel occlusion (LVO) who were not improving with with tenecteplase (TNK), NNT = 9.
Friday’s Spoon Feed:
Dual antiplatelet therapy (DAPT) with ticagrelor plus aspirin vs. placebo in patients with stroke treated with thrombolysis resulted in better 90-day excellent neurological outcome, NNT = 15, without a significant increase in symptomatic intracranial hemorrhage (sICH).

43,898 Listeners

32,100 Listeners

63,929 Listeners

1,866 Listeners

545 Listeners

275 Listeners

506 Listeners

260 Listeners

162 Listeners

59,075 Listeners

87,529 Listeners

111,948 Listeners

269 Listeners

56,508 Listeners

268 Listeners